Search

Additional file 1: Figure S1. (a) SEM of MoSe2-PVP NPs. (b) Histogram of diameter distribution of MoSe2-PVP NPs. Dynamic light scattering and Tyndall photographs of MoSe2-PVP NPs in (c) DMEM, (d) saline, and (e) H2O. Figure S2. (a) The photographs of scavenging ability of MoSe2-PVP NPs for ABTS+. Figure S3. (a) Absorbance of the reaction of H2O2 in the presence of MoSe2-PVP NPs (200 ��g/mL) with time; (b) Kinetic change at 650 nm of POD-like of MoSe2-PVP NPs. (c) Kinetic changes at 340 nm of GPx-like of MoSe2-PVP NPs. Figure S4. The safety of MoSe2-PVP NPs in vitro. (a) Cells viabilities of 266-6 cells after cultured with different concentrations of MoSe2-PVP NPs. (b) The photographs of Live/Dead staining corresponding to (a), b: control, c: 50 ��g/mL, d: 100 ��g/mL. Representative graphics are shown, n = 3 independent experiments. Figure S5. (a-i) Hematological test results of mice after the injection with MoSe2-PVP NPs.

Additional file 1. 1. Materials. 2. Characterization of IrO2@MSN@PDA-BSA NPs. Fig. S1. (a) The TEM images of IrO2@MSN@PDA-BSA NPs; (b) the corresponding size distributions of IrO2-PVP nanoparticles. Fig. S2. EDS spectra of IrO2@MSN@PDA-BSA NPs. Fig. S3. FTIR spectra of PVP, PDA, and IrO2@MSN@PDA-BSA NPs. Fig. S4. Release of Ce6 from IrO2@MSN@PDA-BSA(Ce6) NPs. Fig. S5. Variation of the dissolved oxygen (DO) content at different pH values (pH 6.0 and 7.4). Fig. S6. Routine blood test of IrO2@MSN@PDA-BSA(Ce6) treated KM mice fed for different days.